CD2AP and focal segmental glomerulosclerosis: The worsening of the kidney phenotype is a significant finding when considering treatment strategies for kidney diseases associated with impairment of CD2AP, such as FSGS.45, 46 Mutations in CD2AP observed in FSGS typically lead to reduced expression or absence of CD2AP or render CD2AP biologically defected.45, 46 This could lead to increased tankyrase activity in podocytes.